{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T07:33:58Z","timestamp":1793345638230,"version":"4.5.0"},"reference-count":106,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81473091"],"award-info":[{"award-number":["81473091"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U1170302"],"award-info":[{"award-number":["U1170302"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81303270"],"award-info":[{"award-number":["81303270"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81160543"],"award-info":[{"award-number":["81160543"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004912","name":"Sichuan University","doi-asserted-by":"publisher","award":["2015SCU04A41"],"award-info":[{"award-number":["2015SCU04A41"]}],"id":[{"id":"10.13039\/501100004912","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shenyang Pharmaceutical University Scientific Research Fund","award":["ZCJJ2013407"],"award-info":[{"award-number":["ZCJJ2013407"]}]},{"name":"Jilin Science and Technology","award":["20130204058YY"],"award-info":[{"award-number":["20130204058YY"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.ejmech.2015.12.016","type":"journal-article","created":{"date-parts":[[2015,12,17]],"date-time":"2015-12-17T14:09:10Z","timestamp":1450361350000},"page":"495-504","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":85,"special_numbering":"C","title":["Recent advances in the development of dual VEGFR and c-Met small molecule inhibitors as anticancer drugs"],"prefix":"10.1016","volume":"108","author":[{"given":"Jin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangdong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingnan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingrui","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouyue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2015.12.016_bib1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3322\/caac.20140","volume":"62","author":"Kushi","year":"2012","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ejmech.2015.12.016_bib2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA A Cancer J. Clin."},{"key":"10.1016\/j.ejmech.2015.12.016_bib3","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nrc3599","article-title":"Cancer drug resistance: an evolving paradigm","volume":"13","author":"Holohan","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2015.12.016_bib4","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1183\/09059180.00008913","article-title":"Therapeutic options targeting angiogenesis in nonsmall cell lung cancer","volume":"23","author":"Crin\u00f2","year":"2014","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.ejmech.2015.12.016_bib5","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.canlet.2014.11.048","article-title":"Regulators of carcinogenesis: emerging roles beyond their primary functions","volume":"357","author":"Jia","year":"2015","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2015.12.016_bib6","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2174\/1568026053507732","article-title":"The Hedgehog signaling pathway as a target for anticancer drug discovery","volume":"5","author":"Borzillo","year":"2005","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2015.12.016_bib7","first-page":"1","article-title":"Sustained proliferation in cancer: mechanisms and novel therapeutic targets","volume":"15","author":"Feitelson","year":"2015","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.ejmech.2015.12.016_bib8","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1038\/70928","article-title":"Clinical applications of angiogenic growth factors and their inhibitors","volume":"5","author":"Ferrara","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2015.12.016_bib9","doi-asserted-by":"crossref","unstructured":"D.R. Robinson, Y.M. Wu, S.F. Lin, The protein tyrosine kinase family of the human genome, Oncogene 19 (49) 5548\u20135557.","DOI":"10.1038\/sj.onc.1203957"},{"key":"10.1016\/j.ejmech.2015.12.016_bib10","doi-asserted-by":"crossref","first-page":"5548","DOI":"10.1038\/sj.onc.1203957","article-title":"The protein tyrosine kinase family of the human genome","volume":"19","author":"Robinson","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2015.12.016_bib11","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0092-8674(00)00114-8","article-title":"Cell signaling by receptor tyrosine kinases","volume":"103","author":"Schlessinger","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2015.12.016_bib12","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1124\/mol.112.084111","volume":"83","author":"Singleton","year":"2013","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2015.12.016_bib13","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.18632\/oncotarget.2987","article-title":"Multiple receptor tyrosine kinase activation attenuates therapeutic efficacy of the fibroblast growth factor receptor 2 inhibitor AZD4547 in FGFR2 amplified gastric cancer","volume":"6","author":"Chang","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2015.12.016_bib14","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0065-7743(00)35012-6","article-title":"Anti-angiogenesis as a therapeutic strategy for cancer","volume":"35","author":"Fantl","year":"2000","journal-title":"Annu. Rep. Med. Chem."},{"key":"10.1016\/j.ejmech.2015.12.016_bib15","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1128\/MCB.01592-13","article-title":"Clinical targeting of mutated and wild-type protein tyrosine kinases in cancer","volume":"34","author":"Drake","year":"2014","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2015.12.016_bib16","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.2174\/138161210791209027","article-title":"Targeting protein tyrosine phosphatases for anticancer drug discovery","volume":"16","author":"Scott","year":"2010","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ejmech.2015.12.016_bib17","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/S1471-4914(02)02306-7","article-title":"The ErbB receptor family: a therapeutic target for cancer","volume":"8","author":"de Bono","year":"2002","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.ejmech.2015.12.016_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3748\/wjg.14.1","article-title":"Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer","volume":"14","author":"Hopfner","year":"2008","journal-title":"World J. Gastroentero"},{"key":"10.1016\/j.ejmech.2015.12.016_bib19","article-title":"Theragnostic imaging using radiolabeled antibodies and tyrosine kinase inhibitors","author":"Yoshimoto","year":"2015","journal-title":"Sci. World J. 2015"},{"key":"10.1016\/j.ejmech.2015.12.016_bib20","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1126\/science.7892601","article-title":"Tyrosine kinase inhibition - an approach to drug development","volume":"267","author":"Levitzki","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2015.12.016_bib21","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1517\/17460441.2014.865012","article-title":"Novel approaches to the development of tyrosine kinase inhibitors and their role in the fight against cancer","volume":"9","author":"Z\u00e1me\u010dn\u00edkova","year":"2014","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2015.12.016_bib22","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S1471-4914(01)02217-1","article-title":"Receptor tyrosine kinases as targets for anticancer drugs","volume":"8","author":"Zwick","year":"2002","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.ejmech.2015.12.016_bib23","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.critrevonc.2013.05.009","article-title":"Tyrosine kinase inhibitors (TKIs) in human and pet tumours with special reference to breast cancer: a comparative review","volume":"88","author":"Ranieri","year":"2013","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ejmech.2015.12.016_bib24","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1111\/bcp.12231","article-title":"Incidence and relative risk of hepatic toxicity in patients treated with anti-angiogenic tyrosine kinase inhibitors for malignancy","volume":"77","author":"Iacovelli","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2015.12.016_bib25","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0163-7258(02)00179-1","article-title":"Protein kinases as targets for anticancer agents: from inhibitors to useful drugs","volume":"93","author":"Fabbro","year":"2002","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2015.12.016_bib26","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1358\/dof.2003.028.07.857184","article-title":"Tyrosine kinase targets in drug discovery","volume":"28","author":"Grosios","year":"2003","journal-title":"Drug Future"},{"key":"10.1016\/j.ejmech.2015.12.016_bib27","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1152\/physiol.00045.2009","article-title":"Roles for growth factors in Cancer progression","volume":"25","author":"Witsch","year":"2010","journal-title":"Physiology"},{"key":"10.1016\/j.ejmech.2015.12.016_bib28","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/jnci\/82.1.4","article-title":"What is the evidence that tumors are angiogenesis dependent?","volume":"82","author":"Folkman","year":"1990","journal-title":"J.\u00a0Nati Cancer Inst."},{"key":"10.1016\/j.ejmech.2015.12.016_bib29","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/nm0603-653","article-title":"Angiogenesis in health and disease","volume":"9","author":"Carmeliet","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2015.12.016_bib30","doi-asserted-by":"crossref","first-page":"13932","DOI":"10.1073\/pnas.1309629110","article-title":"Vascular endothelial growth factor-dependent spatiotemporal dual roles of placental growth factor in modulation of angiogenesis and tumor growth","volume":"110","author":"Yang","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2015.12.016_bib31","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1050-1738(02)00168-8","article-title":"Structure and function of placental growth factor","volume":"12","author":"De Falco","year":"2002","journal-title":"Trends Cardiovasc. Med."},{"key":"10.1016\/j.ejmech.2015.12.016_bib32","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/sonc.2002.37263","article-title":"Role of angiogenesis in tumor growth and metastasis","volume":"29","author":"Folkman","year":"2002","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ejmech.2015.12.016_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4062\/biomolther.2013.113","article-title":"VEGF-vegfr signals in health and disease","volume":"22","author":"Shibuya","year":"2014","journal-title":"Biomol. Ther."},{"key":"10.1016\/j.ejmech.2015.12.016_bib34","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1016\/j.ejca.2013.03.022","article-title":"The progression free survival-plateau with vascular endothelial growth factor receptor inhibitors\u2013is there more to come?","volume":"49","author":"Gr\u00fcnwald","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejmech.2015.12.016_bib35","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s10517-012-1612-0","article-title":"Ligand-receptor assay for evaluation of functional activity of human recombinant VEGF and VEGFR-1 extracellular fragment","volume":"152","author":"Leopol'd","year":"2012","journal-title":"Bull. Exp. Biol. Med."},{"key":"10.1016\/j.ejmech.2015.12.016_bib36","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1023\/A:1006358220123","article-title":"Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors","volume":"18","author":"Schlaeppi","year":"1999","journal-title":"Cancer metast. Rev."},{"key":"10.1016\/j.ejmech.2015.12.016_bib37","first-page":"977","article-title":"Comparison of the prognosis indication of VEGFR-1 and VEGFR-2 and Tie2 receptor expression in breast carcinoma","volume":"26","author":"Meunier-Carpentier","year":"2005","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ejmech.2015.12.016_bib38","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/(SICI)1097-0045(20000515)43:3<184::AID-PROS4>3.0.CO;2-6","article-title":"Vascular endothelial growth factor-A expression in the rat ventral prostate gland and the early effects of castration","volume":"43","author":"Burchardt","year":"2000","journal-title":"Prostate"},{"key":"10.1016\/j.ejmech.2015.12.016_bib39","first-page":"938","article-title":"Vascular endothelial growth factor, hepatocyte growth factor\/scatter factor, basic fibroblast growth factor, and placenta growth factor in human meningiomas and their relation to angiogenesis and malignancy","volume":"46","author":"Lamszus","year":"2000","journal-title":"Neurosurgery"},{"key":"10.1016\/j.ejmech.2015.12.016_bib40","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.bcmd.2006.12.003","article-title":"Vascular endothelial growth factor family of ligands and receptors: Review","volume":"38","author":"Otrock","year":"2007","journal-title":"Blood. Cell. Mol. Dis."},{"key":"10.1016\/j.ejmech.2015.12.016_bib41","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0092-8674(00)81402-6","article-title":"Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor","volume":"92","author":"Soker","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2015.12.016_bib42","doi-asserted-by":"crossref","first-page":"5598","DOI":"10.1038\/sj.onc.1203855","article-title":"Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis","volume":"19","author":"Karkkainen","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2015.12.016_bib43","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1038\/sj.onc.1203533","article-title":"Roles of two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF effects in human vascular endothelial calls","volume":"19","author":"Kanno","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2015.12.016_bib44","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1182\/blood.V87.8.3336.bloodjournal8783336","article-title":"Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1","volume":"87","author":"Barleon","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2015.12.016_bib45","first-page":"135","article-title":"A\u00a0unique signal-transduction from flt tyrosine kinase, a receptor for vascular endothelial growth-factor Vegf","volume":"10","author":"Seetharam","year":"1995","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2015.12.016_bib46","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1247\/csf.26.25","article-title":"Structure and function of VEGF\/VEGF-receptor system involved in angiogenesis","volume":"26","author":"Shibuya","year":"2001","journal-title":"Cell Struct. Funct."},{"key":"10.1016\/j.ejmech.2015.12.016_bib47","doi-asserted-by":"crossref","first-page":"387","DOI":"10.2174\/138161206775201910","article-title":"VEGF inhibitors in cancer therapy","volume":"12","author":"Cardones","year":"2006","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ejmech.2015.12.016_bib48","doi-asserted-by":"crossref","first-page":"18","DOI":"10.2174\/138955711793564015","article-title":"Recent progress of small molecular VEGFR inhibitors as anticancer agents","volume":"11","author":"Xu","year":"2011","journal-title":"Mini-Rev. Med. Chem."},{"key":"10.1016\/j.ejmech.2015.12.016_bib49","doi-asserted-by":"crossref","first-page":"920","DOI":"10.2174\/138955711797068355","article-title":"Recent advances in antiangiogenic agents with VEGFR as target","volume":"11","author":"Zhang","year":"2011","journal-title":"Mini-Rev. Med. Chem."},{"key":"10.1016\/j.ejmech.2015.12.016_bib50","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.autrev.2014.11.013","article-title":"Hepatocyte growth factor: a regulator of inflammation and autoimmunity","volume":"14","author":"Molnarfi","year":"2015","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.ejmech.2015.12.016_bib51","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2217\/17460751.2.2.161","article-title":"Hepatocyte growth factor: a regenerative drug for acute hepatitis and liver cirrhosis","volume":"2","author":"Mizuno","year":"2007","journal-title":"Regen. Med."},{"key":"10.1016\/j.ejmech.2015.12.016_bib52","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/0014-5793(87)80475-1","article-title":"Purification and subunit structure of hepatocyte growth factor from rat platelets","volume":"224","author":"Nakamura","year":"1987","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ejmech.2015.12.016_bib53","first-page":"239","article-title":"Scatter factor is a fibroblast-derived modulator of epithelial cell mobility","volume":"327","author":"Stoker","year":"1987","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2015.12.016_bib54","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/342440a0","article-title":"Molecular cloning and expression of human hepatocyte growth factor","volume":"342","author":"Nakamura","year":"1989","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2015.12.016_bib55","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1172\/JCI113334","article-title":"Purification and partial characterization of hepatocyte growth factor from plasma of a patient with fulminant hepatic failure","volume":"81","author":"Gohda","year":"1988","journal-title":"J.\u00a0Clin. Invest"},{"key":"10.1016\/j.ejmech.2015.12.016_bib56","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1038\/sj.emboj.7600243","article-title":"Crystal structure of the HGF beta-chain in complex with the Sema domain of the Met receptor","volume":"23","author":"Stamos","year":"2004","journal-title":"Embo J."},{"key":"10.1016\/j.ejmech.2015.12.016_bib57","doi-asserted-by":"crossref","first-page":"5306","DOI":"10.1073\/pnas.0700184104","article-title":"Utilizing the activation mechanism of serine proteases to engineer hepatocyte growth factor into a Met antagonist","volume":"104","author":"Kirchhofer","year":"2007","journal-title":"P.\u00a0Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2015.12.016_bib58","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s11912-007-0005-4","article-title":"c-Met and hepatocyte growth factor: potential as novel targets in cancer therapy","volume":"9","author":"Sattler","year":"2007","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.ejmech.2015.12.016_bib59","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1023\/A:1023768811842","article-title":"c-Met: structure, functions and potential for therapeutic inhibition","volume":"22","author":"Ma","year":"2003","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.ejmech.2015.12.016_bib60","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1073\/pnas.85.1.21","article-title":"Characterizatin of the TPR-MET oncogene p65 and the met protooncogene p140 protein tyrosine kinases","volume":"85","author":"Gonzatti-Haces","year":"1988","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2015.12.016_bib61","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3109\/08977194.2011.585609","article-title":"Paradoxical action of growth factors: antiproliferative and proapoptotic signaling by HGF\/c-MET","volume":"29","author":"Grzelakowska-Sztabert","year":"2011","journal-title":"Growth Factors"},{"key":"10.1016\/j.ejmech.2015.12.016_bib62","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1158\/1535-7163.MCT-10-0122","article-title":"Targeting the HGF\/c-Met axis: state of play","volume":"9","author":"Yap","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ejmech.2015.12.016_bib63","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/376768a0","article-title":"Essential role for the c-met receptor in the migration of myogenic precursor cells into the Limb bud","volume":"376","author":"Bladt","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2015.12.016_bib64","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/373699a0","article-title":"Scatter Factor\/Hepatocyte growth-factor is essential for liver development","volume":"373","author":"Schmidt","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2015.12.016_bib65","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/373702a0","article-title":"Placental defect and embryonic lethality in mice lacking hepatocyte growth Factor\/Scatter factor","volume":"373","author":"Uehara","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2015.12.016_bib66","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/6310","article-title":"Hepatocyte growth factor, a versatile signal for developing neurons","volume":"2","author":"Maina","year":"1999","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.ejmech.2015.12.016_bib67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2008.10.045","article-title":"MET receptor tyrosine kinase as a therapeutic anticancer target","volume":"280","author":"Stellrecht","year":"2009","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2015.12.016_bib68","first-page":"5117","article-title":"Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR\/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice","volume":"60","author":"Brekken","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2015.12.016_bib69","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0002-9440(10)63273-7","article-title":"Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts","volume":"165","author":"Inai","year":"2004","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ejmech.2015.12.016_bib70","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/nm0901-987","article-title":"Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy","volume":"7","author":"Jain","year":"2001","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2015.12.016_bib71","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1126\/science.1104819","article-title":"Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy","volume":"307","author":"Jain","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2015.12.016_bib72","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1158\/0008-5472.CAN-05-1824","article-title":"Antiangiogenic therapy decreases integrin expression in normalized tumor blood vessels","volume":"66","author":"Yao","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2015.12.016_bib73","doi-asserted-by":"crossref","first-page":"833","DOI":"10.5483\/BMBRep.2008.41.12.833","article-title":"The hepatocyte growth factor\/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis","volume":"41","author":"You","year":"2008","journal-title":"Bmb. Rep."},{"key":"10.1016\/j.ejmech.2015.12.016_bib74","doi-asserted-by":"crossref","first-page":"4743","DOI":"10.1200\/JCO.2007.12.3026","article-title":"Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non-small-cell lung cancer","volume":"25","author":"Herbst","year":"2007","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ejmech.2015.12.016_bib75","first-page":"2749","article-title":"Placental growth factor is a survival factor for tumor endothelial cells and macrophages","volume":"62","author":"Adini","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2015.12.016_bib76","doi-asserted-by":"crossref","first-page":"4816","DOI":"10.1182\/blood-2002-06-1731","article-title":"HGF receptor up-regulation contributes to the angiogenic phenotype of human endothelial cells and promotes angiogenesis in\u00a0vitro","volume":"101","author":"Ding","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2015.12.016_bib77","doi-asserted-by":"crossref","first-page":"833","DOI":"10.5483\/BMBRep.2008.41.12.833","article-title":"The hepatocyte growth factor\/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis","volume":"41","author":"You","year":"2008","journal-title":"BMB Rep."},{"key":"10.1016\/j.ejmech.2015.12.016_bib78","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/onc.2013.539","article-title":"Effective inhibition of c-MET-mediated signaling, growth and migration of ovarian cancer cells is influenced by the ovarian tissue microenvironment","volume":"34","author":"Kwon","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2015.12.016_bib79","doi-asserted-by":"crossref","first-page":"13768","DOI":"10.3390\/ijms150813768","article-title":"Small-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapies","volume":"815","author":"Hojjat-Farsangi","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2015.12.016_bib80","doi-asserted-by":"crossref","first-page":"6552","DOI":"10.1016\/j.bmcl.2009.10.040","article-title":"N-(4-(6,7-Disubstituted-quinolin-4-yloxy)-3-fluorophenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met\/VEGFR2 receptor tyrosine kinase inhibitors","volume":"19","author":"Mannion","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2015.12.016_bib81","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.beem.2008.09.012","article-title":"Receptor tyrosine kinase inhibitors in thyroid cancer","volume":"22","author":"Castellone","year":"2008","journal-title":"Best. Pract. Res. Cl. En."},{"key":"10.1016\/j.ejmech.2015.12.016_bib82","doi-asserted-by":"crossref","first-page":"462","DOI":"10.2174\/187152008784533035","article-title":"Antiangiogenic drugs and tyrosine kinases","volume":"8","author":"Timar","year":"2008","journal-title":"Anti-Cancer Agent Me"},{"key":"10.1016\/j.ejmech.2015.12.016_bib83","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","article-title":"Cabozantinib (XL184), a novel met and VEGFR2 inhibitor, simultaneously Suppresses metastasis, angiogenesis, and tumor growth","volume":"10","author":"Yakes","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ejmech.2015.12.016_bib84","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1200\/JCO.2010.32.4145","article-title":"Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid Cancer","volume":"29","author":"Kurzrock","year":"2011","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ejmech.2015.12.016_bib85","first-page":"112","article-title":"XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC","volume":"13","author":"Zhang","year":"2010","journal-title":"Idrugs"},{"key":"10.1016\/j.ejmech.2015.12.016_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/S1359-6349(10)72104-2","article-title":"Phase 2 results of XL184 in a cohort of patients (pts) with advanced non-small cell lung cancer (NSCLC)","volume":"8","author":"Yasenchak","year":"2010","journal-title":"Ejc. Suppl."},{"key":"10.1016\/j.ejmech.2015.12.016_bib87","doi-asserted-by":"crossref","first-page":"8009","DOI":"10.1158\/0008-5472.CAN-08-4889","article-title":"Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases","volume":"69","author":"Qian","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2015.12.016_bib88","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1158\/1078-0432.CCR-10-3387","article-title":"Foretinib (GSK1363089), an orally available multikinase inhibitor of c-met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian Cancer metastasis","volume":"17","author":"Zillhardt","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2015.12.016_bib89","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s10456-011-9243-z","article-title":"Foretinib demonstrates anti-tumor activity and improves overall survival in preclinical models of hepatocellular carcinoma","volume":"15","author":"Huynh","year":"2012","journal-title":"Angiogenesis"},{"key":"10.1016\/j.ejmech.2015.12.016_bib90","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1007\/s10637-011-9699-0","article-title":"Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks","volume":"30","author":"Kataoka","year":"2012","journal-title":"Invest. New. Drug"},{"key":"10.1016\/j.ejmech.2015.12.016_bib91","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1158\/1535-7163.MCT-13-0459","article-title":"The novel VEGF Receptor\/MET-targeted kinase inhibitor TAS-115 has marked in\u00a0vivo antitumor properties and a favorable tolerability profile","volume":"12","author":"Fujita","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ejmech.2015.12.016_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/S0959-8049(12)72236-0","article-title":"Identification of gene expression Signature to predict anti-tumor efficacy of MET\/VEGFR inhibitor, TAS-115","volume":"48","author":"Itadani","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejmech.2015.12.016_bib93","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ejmech.2013.11.023","article-title":"A\u00a0development of chimeric VEGFR2 TK inhibitor based on two ligand conformers from PDB: 1Y6A complex\u2013medicinal chemistry consequences of a TKs analysis","volume":"72","author":"Lintnerov\u00e1","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2015.12.016_bib94","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1349-7006.2009.01343.x","article-title":"E7050: a dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models","volume":"101","author":"Nakagawa","year":"2010","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ejmech.2015.12.016_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/S1359-6349(10)71801-2","article-title":"Discovery of BMS-817378: a novel prodrug of the dual Met\/VEGFR-2 inhibitor BMS-794833","volume":"8","author":"Borzilleri","year":"2010","journal-title":"Ejc. Suppl."},{"key":"10.1016\/j.ejmech.2015.12.016_bib96","doi-asserted-by":"crossref","DOI":"10.1016\/S1359-6349(10)71811-5","article-title":"Preclinical studies and characterization of BMS-794833, a small molecule inhibitor of Met and VEGFR-2 kinases","volume":"8","author":"Fargnoli","year":"2010","journal-title":"Ejc. Suppl."},{"key":"10.1016\/j.ejmech.2015.12.016_bib97","doi-asserted-by":"crossref","DOI":"10.1016\/S1359-6349(08)72013-5","article-title":"Preclinical pharmacodynamic markers of MGCD265, a potent orally active c-Met\/VEGFR multitargeted kinase inhibitor in phase I clinical trials","volume":"6","author":"Beaulieu","year":"2008","journal-title":"Ejc. Suppl."},{"key":"10.1016\/j.ejmech.2015.12.016_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/S1359-6349(10)72103-0","article-title":"MGCD265, an orally active Met\/VEGFR multitargeted kinase inhibitor, in combination with docetaxel: clinical and preclinical experience","volume":"8","author":"O'Dwyer","year":"2010","journal-title":"Ejc. Suppl."},{"key":"10.1016\/j.ejmech.2015.12.016_bib99","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0959-8049(12)72110-X","article-title":"A\u00a0novel assay for the met inhibitory activity of MGCD265 in plasma from solid tumor patients in a dose escalating phase I study","volume":"48","author":"Fournel","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejmech.2015.12.016_bib100","doi-asserted-by":"crossref","first-page":"6836","DOI":"10.1016\/j.bmcl.2009.10.095","article-title":"N3-Arylmalonamides: a new series of thieno[3,2-b]pyridine based inhibitors of c-Met and VEGFR2 tyrosine kinases","volume":"19","author":"Saavedra","year":"2009","journal-title":"Bioorg Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2015.12.016_bib101","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1016\/j.bmcl.2008.04.009","article-title":"M.Dubay, R. Pascal, J. Gillespie, Z. Jin, J. Wang, J.M. Besterman, A.R. MacLeod, A. Vaisburg, discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases","volume":"18","author":"Claridge","year":"2008","journal-title":"Bioorg Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2015.12.016_bib102","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.bmcl.2009.01.068","article-title":"N-(3-fluoro-4-(2-arylthieno[3,2-b]pyridin-7-yloxy)phenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met\/VEGFR2 receptor tyrosine kinase inhibitors","volume":"19","author":"Raeppel","year":"2009","journal-title":"Bioorg Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2015.12.016_bib103","doi-asserted-by":"crossref","first-page":"6666","DOI":"10.1021\/jm049237m","article-title":"Identification of 7-phenylaxaminothieno[3,2-b]pyridine-6-carbonitriles as a new class of Src kinase inhibitors","volume":"47","author":"Boschelli","year":"2004","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2015.12.016_bib104","doi-asserted-by":"crossref","first-page":"4681","DOI":"10.1016\/j.bmcl.2005.07.061","article-title":"Inhibition of Src kinase activity by 7-[(2,4-dichloro-5-methoxyphenyl)-amino]-2-heteroaryl-thieno[3,2-b]pyridine-6-carbonitriles","volume":"15","author":"Boschelli","year":"2005","journal-title":"Bioorg Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2015.12.016_bib105","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1021\/jm050175p","article-title":"Synthesis and Src kinase inhibitory activity of 2-phenyl- and 2-thienyl-7-phenylaminothieno[3,2-b]pyridine-6-carbonitriles","volume":"48","author":"Boschelli","year":"2005","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2015.12.016_bib106","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1158\/1535-7163.MCT-12-1011","article-title":"A\u00a0novel inhibitor of c-met and VEGF receptor tyrosine kinases with a broad Spectrum of in\u00a0vivo antitumor activities","volume":"12","author":"Awazu","year":"2013","journal-title":"Mol. Cancer Ther."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523415304025?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523415304025?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,12]],"date-time":"2020-09-12T17:46:45Z","timestamp":1599932805000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523415304025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":106,"alternative-id":["S0223523415304025"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2015.12.016","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent advances in the development of dual VEGFR and c-Met small molecule inhibitors as anticancer drugs","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2015.12.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}